Company
Headquarters: Melbourne, VIC, Australia
CEO: Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA
A$851.7 Million
AUD as of July 1, 2024
US$567.2 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRàNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | A$81.8 M |
| EBITDA | A$49.6 M |
| Gross Profit TTM | A$69.5 M |
| Profit Margin | 36.88% |
| Operating Margin | 42.37% |
| Quarterly Revenue Growth | 11.70% |
Clinuvel Pharmaceuticals Limited has the following listings and related stock indices.
Stock: ASX: CUV
Stock: FSX: UR9
Stock: Munich: UR9